Cell Rejuvenation Milestone Tracker (2026)
In our longevity market deck, you will find everything you need to understand the market
Cell Rejuvenation Milestone Tracker
This table tracks 35 development milestones for four leading cellular reprogramming companies, with each cell rated Yes, No, Kind of, or Unclear based on publicly verifiable evidence as of April 2026. Columns are ordered from most clinically advanced (left) to earliest stage (right).
The first column lists progressively harder questions, from basic platform definition to repeatable human efficacy, while each company column shows how far that program has actually gone. If you want to dig deeper into this market, you can check out our longevity market report.
| Question | Life Biosciences | NewLimit | Retro Biosciences | Altos Labs |
|---|---|---|---|---|
| Has the company announced a rejuvenation program? | Yes | Yes | Yes | Yes |
| Does it explicitly target cellular reprogramming? | Yes | Yes | Yes | Yes |
| Has it defined a core scientific thesis? | Yes | Yes | Yes | Yes |
| Has it named target tissues or cells? | Yes | Yes | Yes | Kind of |
| Has it defined a disease-first strategy? | Yes | Yes | Yes | Kind of |
| Has it disclosed a lead program? | Yes | Yes | Yes | No |
| Has it named a therapeutic modality? | Yes | Yes | Yes | Kind of |
| Has it described its delivery approach? | Yes | Yes | Yes | Kind of |
| Has it named a target indication? | Yes | Yes | Yes | No |
| Has it named a patient population? | Yes | Kind of | Yes | No |
| Has it shown rejuvenation in cell models? | Yes | Yes | Yes | Yes |
| Has it shown functional gains in animals? | Yes | Yes | Unclear | Kind of |
| Has it shown biomarker reversal in animals? | Yes | Yes | Unclear | Yes |
| Has it shown controlled partial reprogramming? | Yes | Yes | Kind of | Yes |
| Has it shown durability after dosing? | Yes | Kind of | Unclear | Unclear |
| Has it shown large-animal safety? | Yes | No | No | Unclear |
| Has it shown nonhuman primate data? | Yes | No | No | Unclear |
| Has it published peer-reviewed preclinical work? | Yes | Kind of | Kind of | Yes |
| Has it selected a clinical delivery route? | Yes | Yes | Yes | No |
| Has it identified a primary endpoint? | Yes | Kind of | Yes | No |
| Has it identified a biomarker endpoint? | Yes | Kind of | Yes | No |
| Has it named a clinical candidate? | Yes | Kind of | Yes | No |
| Has it started IND-enabling studies? | Yes | No | Yes | Unclear |
| Has it received regulatory clearance? | Yes | No | Kind of | No |
| Has it registered a human trial? | Yes | No | Yes | No |
| Has the first patient been dosed? | Unclear | No | Yes | No |
| Has it reported human safety data? | No | No | No | No |
| Has it reported human biomarker data? | No | No | No | No |
| Has it reported human functional data? | No | No | No | No |
| Has it partnered with pharma on this platform? | No | Yes | Yes | No |
| Has it expanded beyond one indication? | Yes | Yes | Yes | Kind of |
| Has it advanced beyond first-in-human? | No | No | No | No |
| Has it shown repeatable human efficacy? | No | No | No | No |
| Has it started a registrational path? | No | No | No | No |
| Has it built a multi-program clinical pipeline? | No | No | No | No |
This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
Insights
We compared four leading cellular reprogramming companies across 35 milestones spanning platform definition, preclinical evidence, regulatory progress, clinical development, and pipeline expansion: Life Biosciences, NewLimit, Retro Biosciences, and Altos Labs. Each one was scored using publicly verifiable evidence as of April 2026 to separate headline momentum from verified therapeutic progress. Here is what stood out.
- Life Biosciences has the smallest budget among the four leaders. It reached the clinic first. Capital does not buy speed in aging biology.
- The company with the largest budget is Altos Labs, with $3 billion in initial funding. It has no disclosed clinical program. Its resources bought optionality, not velocity.
- Over $4 billion has been invested across these four companies alone. None has reported human efficacy data. The entire field of therapeutic cellular reprogramming remains at the hypothesis stage in humans.
- Life Bio dropped MYC from the Yamanaka cocktail, using only OCT4, SOX2, and KLF4. MYC is an oncogene. Removing it likely accelerated FDA clearance by years.
- Life Bio chose the eye as its first target for three strategic reasons. The eye is immunoprivileged, intravitreal delivery is well understood, and visual function is measurable with extreme precision.
- Life Bio's ER-100 uses AAV, a vector that triggers immune responses after one dose. Patients may not be able to receive a second injection. If reprogramming wears off, retreatment becomes a serious problem.
- NewLimit is the only company that rejected Yamanaka factors as its therapeutic payload. It searches thousands of novel transcription factor combinations instead. This is the field's biggest contrarian bet.
- NewLimit claims to have tested over 1,000 times more reprogramming payloads than the rest of the field combined. Its AI systems increase discovery throughput every year. If true, this creates a data moat that competitors cannot replicate.
- Some of NewLimit's novel transcription factors restore youthful function without erasing cell identity. Yamanaka factors compromise cell identity during reprogramming. This difference could make NewLimit's approach fundamentally safer.
- Eli Lilly invested directly in NewLimit's latest funding round. Lilly is riding the GLP-1 wave and does not need longevity PR. This is the strongest pharma endorsement in the reprogramming space.
- Retro Biosciences became a clinical-stage company in late 2025 with its first patient dosed. But its clinical asset is an autophagy pill, not a reprogramming therapy. The reprogramming program remains entirely preclinical.
- The OpenAI-Retro collaboration achieved a 50x improvement in stem cell reprogramming markers. This is full reprogramming to pluripotency, not partial reprogramming. Partial reprogramming is what the therapeutic field actually needs.
- No company has published long-term safety data after partial reprogramming in animals or humans. Tumor risk from uncontrolled reprogramming has not been ruled out. This is the field's most critical unanswered question.
- None of these companies has answered a fundamental question: how often must reprogramming be repeated? The answer determines whether these become cures, chronic treatments, or periodic interventions. The entire business model depends on it.
This chart, featured in our longevity market deck, compares the main business model options for longevity clinics
Which cell rejuvenation company has the most verified deployment progress today?
Life Biosciences has the most verified deployment progress because it is the only company that has crossed the line from platform rhetoric to a named product, an FDA-cleared IND, and a registered first-in-human trial for a specific disease.
The right comparison is not who has the best story, but who has the most verified conversion from platform to product. That means a named candidate, a defined indication, a delivery route, a regulatory interaction, and a human study registration. On that basis, Life Bio is ahead. ER-100 is an AAV-delivered OSK program for optic neuropathies. The company received FDA authorization to proceed on January 15, 2026, announced IND clearance on January 28, 2026, and ClinicalTrials.gov lists NCT07290244 as a Phase 1 study in open-angle glaucoma and NAION.
NewLimit is the strongest preclinical contender. It has disclosed one lead payload, reported 16 payloads with efficacy in animal models, and achieved an 8x specificity improvement in its liver-targeted candidate. But it has no registered trial, no disclosed IND, and no human data.
Retro has real progress at the company level, but much less in reprogramming specifically. Its Phase 1 asset RTR242 is an autophagy small molecule for Alzheimer's, not a reprogramming therapy. The OpenAI collaboration produced in vitro iPSC improvements, not human therapeutic progress.
Altos has the weakest case once branding is stripped out. Its Cell paper on mesenchymal drift is substantial science across more than 40 tissues and 20 diseases. But that is still mechanism-level work. The company has hired a CMO to lead clinical programs, yet no program, no candidate, and no trial have been disclosed.
Which cellular reprogramming company is progressing the fastest right now?
Life Biosciences is progressing the fastest because it moved from preclinical disclosure to FDA-cleared first-in-human reprogramming status in January 2026, a bigger verified step than any recent move by its peers.
On a dated milestone basis, Life Bio's recent trajectory is the clearest. FDA authorization to proceed came on January 15, 2026. IND clearance was announced January 28, 2026. The Phase 1 trial was initiated in Q1 2026. That is a regulator-facing transition into the clinic within weeks.
NewLimit's recent pace is strong but remains one layer earlier. In 2025 it closed a $130 million Series B, disclosed over 3,000 transcription factor sets tested, and reported 8x specificity and 1.6x potency improvements on its lead candidate. That is rapid preclinical progress, but not a stage transition.
Retro became a clinical-stage company by dosing the first RTR242 participant in December 2025. The OpenAI collaboration was also disclosed in August 2025. But these are two different stories: company-level clinical progress via autophagy, and reprogramming progress via in vitro AI-designed factors. The reprogramming arm itself did not cross into human studies.
Altos made meaningful scientific progress in 2025 with the mesenchymal drift paper in Cell and Joan Mannick's CMO appointment. But it still had no disclosed clinical program. That is slower translational velocity than Life Bio and probably slower than NewLimit's candidate development pace.
Which cell rejuvenation company has the clearest path from platform to product?
Life Biosciences has the clearest path from platform to product because the full chain is already defined in public: platform, candidate, indication, delivery route, activation control, regulatory interaction, and human trial design.
Life Bio's platform-to-product conversion is unusually explicit. Platform: partial epigenetic reprogramming using OSK. Product candidate: ER-100. Indications: open-angle glaucoma and NAION. Delivery: intravitreal injection with doxycycline-inducible activation. Development path: FDA-cleared IND and first-in-human Phase 1. That is what a clear path looks like in biotech.
NewLimit may ultimately have a better platform, but its product path is less defined today. It has a liver LNP-mRNA approach, Fierce Biotech identified alcohol-related liver disease as the first target, and NewLimit says it has one preclinical candidate. But no clinical candidate has been formally named, no trial design has been published, and no regulator-facing package is public.
Retro has a clear product path for autophagy, not for reprogramming. Its reprogramming pipeline lists AAV-delivered factors for osteoarthritis and age-related hearing loss, but no named asset or IND disclosure exists for those programs.
Altos has the least clear path. The science thesis is increasingly coherent with the mesenchymal drift framework, but no named product, no clinical protocol, and no indication-specific program have been disclosed.
This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
Which cellular reprogramming company will reach human clinical data first?
Life Biosciences will most likely reach human clinical data first because it already has the only publicly registered human trial for a reprogramming therapy.
Meaningful human data here should mean more than "drug was dosed." It should mean at least a coherent safety package plus interpretable pharmacology or function-adjacent readouts in the intended tissue. For Life Bio, that could be ocular safety, immune observations, and visual assessments in patients with glaucoma or NAION.
NewLimit is not close enough publicly to beat Life Bio to human data. It has a candidate and a likely liver disease path, but no public registry entry and no IND. Retro may generate company-level human data earlier from its RTR242 autophagy trial, but not reprogramming human data. Altos is the least likely to get there first because no trial registration or named candidate exists.
The fastest route to meaningful human data is the route already underway. Life Bio's trial is registered on ClinicalTrials.gov as NCT07290244. No public confirmation of patient dosing exists yet, but enrollment has begun.
Which cell rejuvenation company is most disciplined about safety and controllability?
Life Biosciences is the most disciplined about safety because it combined a local ocular delivery route, removal of the oncogenic MYC factor, a doxycycline-inducible on/off switch, and an FDA-cleared development package.
The safety question splits into controllability of biology, precision of delivery, and regulatory discipline. Life Bio uses OSK rather than OSKM, excluding MYC. It chose intravitreal delivery into one eye rather than systemic delivery. Doxycycline acts as a safety brake: stop the antibiotic, and the reprogramming factors turn off. The program has already survived FDA review into an IND-cleared Phase 1 trial.
NewLimit may have the best intrinsic controllability at the molecular level. Its LNP-mRNA system is transient, liver-targeted, and the company emphasizes requiring multiple youthful functions restored before advancing a candidate. Its 2025 review stated the candidate did not induce liver damage or neoplasia in animals at high doses. But it remains self-disclosed preclinical evidence, not regulator-tested human development.
Retro's flagship reprogramming disclosure is about making Yamanaka-factor variants more potent for iPSC generation. Higher potency is useful but raises concern around overshoot unless paired with a clear control architecture, which has not been publicly disclosed. Altos talks a disciplined biology language, but its public package is too incomplete to rank above Life Bio today.
Which cellular reprogramming company has the most regulator-friendly development package?
Life Biosciences has the most regulator-friendly development package because it already has the only package that has crossed an FDA IND threshold in cellular reprogramming.
Regulators care about defined indication, measurable endpoints, manageable exposure, manufacturing consistency, and a coherent risk-mitigation story. Life Bio's choice of optic neuropathies gives it an unusually clean setup: localized dosing to one eye, ophthalmic monitoring tools with decades of clinical precedent, and visual-function assessments that regulators already understand from the anti-VEGF era.
NewLimit is the best challenger on future regulator-friendliness. Liver-targeted LNP-mRNA is a familiar modality class, and alcohol-related liver disease is a conventional disease framework. But its package is still partly notional in public, with no IND filing or trial registration disclosed.
Retro's regulator-friendly package exists for RTR242 under Australian TGA approval, not for its reprogramming platform. Altos may eventually find a regulator-friendly niche in ex vivo organ rejuvenation, which avoids systemic delivery risks, but that remains concept-stage.
This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups
Which cell rejuvenation company is building the strongest competitive moat?
NewLimit is building the strongest competitive moat because its biggest defensible asset is a compounding data-and-discovery engine rather than a single program lead.
Life Bio's moat is regulatory and temporal: first IND-cleared reprogramming program, first registered human trial. That matters, but it can be eroded if the asset underperforms in patients.
NewLimit's moat is data plus discovery infrastructure. The company says it has discovered 16 payloads active in animal models, 36 active in cells, and over 3,000 transcription factor sets tested across programs. Its AI systems are increasing discovery productivity year over year. If even part of that scales, the moat is not just one candidate but a search-and-learning system that competitors will struggle to replicate quickly. Eli Lilly's direct investment adds an external validation signal that goes beyond startup hype.
Retro's moat is potentially AI-enabled protein design through exclusive access to OpenAI's GPT-4b micro, a model that is not publicly available. That creates an asymmetric advantage, but the disclosed therapeutic result remains narrow. Altos' moat is elite biology and capital, not execution evidence.
Which cellular reprogramming company has the most scalable delivery system?
NewLimit has the most scalable delivery system because liver-targeted LNP-mRNA is the most industrially scalable, repeat-dose-compatible, and commercially plausible delivery approach among the four contenders.
Scalability in this context means manufacturing, tissue access, repeat dosing, cost, and deployability at population scale. NewLimit's lead asset uses lipid nanoparticles to deliver mRNA to liver cells. The liver is a natural destination for LNP systems, mRNA manufacturing is comparatively standardized after the COVID vaccine era, and transient expression is more compatible with repeat dosing than persistent viral gene transfer.
Life Bio's ocular AAV route is strategically smart for a first approval, but it is not the most scalable system. It is localized, procedure-based, and constrained by gene-therapy manufacturing economics and the known redosing challenges of AAV vectors.
Retro's reprogramming delivery is also AAV-based according to its pipeline page, carrying similar scale and repeat-dose constraints. Altos has no clearly disclosed scalable in vivo delivery system. Its ex vivo organ perfusion concept could become clinically important, but it is not deployable across large patient populations the way an LNP drug could be.
Which cell rejuvenation company is the most transparent about its progress?
NewLimit is the most transparent cell rejuvenation company because it publishes the most detailed, regular, and technically specific progress updates among the leading private reprogramming companies.
Transparency here means how easy it is to audit claims from the outside. NewLimit scores best because it repeatedly discloses concrete internal metrics: number of transcription factor sets tested, candidate funnel size, specificity and potency improvements, program expansions, and its explicit operating plan. It publishes bi-monthly updates with actual data figures, which is unusual for a preclinical biotech.
Life Bio is reasonably transparent on milestone-stage matters. It named ER-100, disclosed indications, announced FDA clearance, and registered its trial. That is real transparency on development status. But it is less open than NewLimit on ongoing scientific iteration and internal decision-making.
Retro is selectively transparent. Its pipeline page is useful and the OpenAI post gives substantial technical detail. But the company is otherwise less open on reprogramming development specifics. Altos is the least transparent. It has published important science, but its therapeutic programs remain largely opaque, and its organizational moves have outpaced public program disclosure.
Which cellular reprogramming company is the most overhyped relative to its evidence?
Retro Biosciences is the most overhyped cellular reprogramming company because the intensity of the narrative around it exceeds the amount of verified reprogramming product progress it has actually delivered.
STAT reported in December 2025 that Retro was seeking a $5 billion valuation despite having no clinical data in hand for its reprogramming program. The OpenAI collaboration generated enormous attention, and the company did become clinical-stage in 2025. But the critical mismatch is this: the clinical-stage asset is RTR242, an autophagy small molecule, while the most visible public excitement has centered on reprogramming and AI-designed Yamanaka factors. Those factors have only shown in vitro iPSC-related gains so far.
Life Bio is not overhyped because its claims are anchored by actual regulator-facing progress. NewLimit is not overhyped because its public posture is comparatively technical and data-heavy. Altos is also highly hyped, but the gap is partially blunted by the fact that Altos presents itself more as a deep-science company than as an imminent product company, and its Cell paper is real scientific output.
Retro's valuation narrative, celebrity-backer signal, OpenAI halo, and "clinical-stage" label all create an impression of reprogramming maturity that the public evidence does not support. The company may still become excellent. But today the ratio of excitement to reprogramming-specific verified evidence is highest here.
This chart, featured in our longevity market deck, shows how wearable longevity devices have driven growth in the longevity market over time
This tracker is a live research tool we maintain to assess which cellular reprogramming programs appear closest to delivering a therapeutic product in humans. It is updated as new evidence emerges.
The tracker is focused on one question: how far has each company actually progressed from scientific platform to clinical deployment? It is not designed to score every dimension of a company's potential, its scientific roster, or its long-term thesis.
To be included, a company must have a publicly announced cellular reprogramming program with observable evidence of therapeutic development progress. Companies focused solely on basic research, cosmetic applications, or non-reprogramming longevity approaches are excluded.
The 35 questions are ordered by increasing difficulty. Early rows (program announcement, thesis, target tissue) are easy to achieve. Later rows (human efficacy, registrational path, multi-program pipeline) are hard. This structure makes it visually obvious where each program's evidence runs out.
Each cell is rated Yes, No, Kind of, or Unclear. "Yes" means we found credible, publicly verifiable evidence. "No" means we found no such evidence. "Kind of" means partial, ambiguous, or heavily caveated evidence exists. "Unclear" means the company has not disclosed enough information for us to assess.
We rely on direct and credible sources: company press releases, FDA filings, ClinicalTrials.gov registrations, peer-reviewed publications, IPO filings, conference presentations, and reporting from publications like Fierce Biotech, STAT, and Endpoints News. We do not treat social media posts, investor decks, or unverified claims as strong evidence on their own.
When evidence is partial or hard to verify, we score conservatively. The tracker should be read as directional, not absolute. The goal is a disciplined view of which programs seem closest to therapeutic reality, based on what can be shown today. You can find more details and additional analysis in our longevity market report.
As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing
Related blog posts
- The startups that have raised the most funding in the longevity market
- The most highly valued startups in the longevity market
- The full range of business models in the longevity market
- Which longevity segment is the most investable today?
- How strong is fundraising in the longevity market right now?
